Claims
- 1. A method for preventing an increase in matrix metalloproteinase (MMP) activity or reducing MMP activity in a subject, said method comprising the step of:
a) administering to said subject a therapeutically effective amount of an aldosterone blocker.
- 2. The method of claim 1, wherein said aldosterone antagonist comprises eplerenone.
- 3. The method of claim 1, wherein said aldosterone antagonist comprises spironolactone.
- 4. The method of claim 1, wherein said MMP activity is modulated in myocardial tissue.
- 5. The method of claim 1, wherein said MMP activity is modulated in left ventricular tissue.
- 6. The method of claim 1, wherein said MMP activity is modulated in the tissue of a member selected from the group consisting of heart, kidney and brain.
- 7. The method of claim 1, wherein said MMP activity is modulated in a coronary artery.
- 8. The method of claim 1, wherein said MMP activity is MMP-2 activity.
- 9. The method of claim 1, wherein said MMP activity is MMP-9 activity.
- 10. The method of claim 1, wherein said MMP activity is MMP-13 activity.
- 11. The method of claim 1, wherein said MMP activity is MMP-2 activity, MMP-9 activity or MMP-13 activity.
- 12. The method of claim 1, wherein said MMP activity is modulated in said subject suffering from hypertension.
- 13. The method of claim 1, wherein said MMP activity is modulated in said subject suffering from heart failure.
- 14. The method of claim 13, wherein said heart failure is selected from the group consisting of class-II, class-III and class-IV heart failure.
- 15. The method of claim 1, wherein said MMP activity is modulated in said subject suffering from cardiac fibrosis.
- 16. The method of claim 1, wherein said MMP activity is modulated in said subject suffering from atherosclerosis.
- 17. The method of claim 1, wherein said MMP activity is modulated in said subject suffering from enlargement of the heart.
- 18. The method of claim 1, wherein said MMP activity is modulated in said subject suffering from left ventricular dilation.
- 19. The method of claim 1, wherein said MMP activity is modulated in said subject suffering from progressive left ventricular failure.
- 20. The method of claim 19, wherein said MMP activity is modulated in said subject having a left ventricular ejection fraction less than about 40%.
- 21. The method of claim 1, wherein said subject is a mammal.
- 22. The method of claim 21, wherein said mammal is a human.
- 23. The method of claim 22, wherein said human has symptoms of or has had symptoms of a condition selected from the group consisting of heart failure, renal disease, stroke, diabetes and syndrome X.
- 24. The method of claim 2, wherein said administering step comprises administering a daily dose of said eplerenone from about 25 mg to about 400 mg.
- 25. The method of claim 24, wherein said daily dose is provided in a single daily dose.
- 26. The method of claim 24, wherein said daily dose is provided in multiple divided doses.
- 27. The method of claim 24, wherein said daily dose is administered orally.
- 28. The method of claim 1, wherein said aldosterone blocker inhibits said MMP activity.
- 29. The method of claim 2, wherein said eplerenone inhibits said MMP activity.
- 30. The method of claim 1, wherein said aldosterone blocker is an epoxy-steroidal aldosterone blocker.
- 31. The method of claim 30, wherein said epoxy-steroidal aldosterone blocker is combined with a pharmaceutically acceptable carrier.
- 32. The method of claim 22, wherein said human has symptoms of or has had symptoms of syndrome X, atherosclerosis or myocardial infarction.
- 33. The method of claim 22, wherein said human has symptoms of or has had symptoms of coronary arterial disease.
- 34. The method of claim 1, wherein the aldosterone blocker is a selective aldosterone blocker.
- 35. The method of claim 1, wherein said MMP activity is modulated in renal tissue.
- 36. The method of claim 1, wherein said MMP activity is modulated in the vascular tissue of a member selected from the group consisting of heart, kidney and brain.
- 37. The method of claim 22, wherein said mammal has symptoms of or has had symptoms of a condition selected from the group consisting of heart failure, renal disease, stroke, diabetes and syndrome X.
- 38. The method of claim 32, wherein said mammal has symptoms of or has had symptoms of syndrome X, atherosclerosis or myocardial infarction.
- 39. The method of claim 33, wherein said mammal has symptoms of or has had symptoms of coronary arterial disease.
Parent Case Info
[0001] This application is a non-provisional of provisional application Serial No. 60/405,292 filed Aug. 23, 2003, the contents of which is incorporated herein in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60405292 |
Aug 2002 |
US |